scholarly journals ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents

2017 ◽  
Vol 105 (3) ◽  
pp. 266-280 ◽  
Author(s):  
Marianne Pavel ◽  
Juan W. Valle ◽  
Barbro Eriksson ◽  
Anja Rinke ◽  
Martyn Caplin ◽  
...  
Keyword(s):  
Systemic Therapy ◽  
Standards Of Care ◽  
Neuroendocrine Neoplasms ◽  
Targeted Agents ◽  
Consensus Guidelines

scholarly journals ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Chemotherapy

2017 ◽  
Vol 105 (3) ◽  
pp. 281-294 ◽  
Author(s):  
Rocio Garcia-Carbonero ◽  
Anja Rinke ◽  
Juan W. Valle ◽  
Nicola Fazio ◽  
Martyn Caplin ◽  
...  
Keyword(s):  
Systemic Therapy ◽  
Standards Of Care ◽  
Neuroendocrine Neoplasms ◽  
Consensus Guidelines

Genomic Profiles and Current Therapeutic Agents in Neuroendocrine Neoplasms

2020 ◽  
Vol 21 (4) ◽  
pp. 389-405
Author(s):  
Akihiro Ohmoto ◽  
Chigusa Morizane
Keyword(s):  
Current Knowledge ◽  
Treatment Strategies ◽  
Phase Iii ◽  
World Health ◽  
Standards Of Care ◽  
Neuroendocrine Neoplasms ◽  
Targeted Agents ◽  
Poorly Differentiated ◽  
Molecular Targeted Agents ◽  
Well Differentiated

Neuroendocrine neoplasms (NENs) are rare tumors that mainly occur in the gastroenteropancreatic (GEP) tract and lungs. According to the current World Health Organization classification for GEP-NENs and lung NENs, treatment strategies differ for well-differentiated and poorly differentiated subtypes. For well-differentiated GEP-NENs, somatostatin analogues (SSA), peptide receptor radionuclide therapy, and molecular-targeted agents are approved as the standards of care based on phase III clinical trial data. Promising data regarding the use of everolimus and the novel SSA pasireotide for lung NENs are emerging, though additional studies are required to confirm these effects. For poorly differentiated tumors from the GEP tract and lung, a platinum-based cytotoxic regimen is widely used. Genomic analysis has recently revealed a diverse pattern of primary organ-dependent mutations, and the use of traditional treatment strategies versus organ-specific strategies is currently under discussion. In addition, clinical trials for several molecular-targeted agents and immune checkpoint inhibitors for the treatment of NENs are currently underway. Accumulating genomic information is expected to contribute to the development of novel therapies for other organ-derived NENs or poorly differentiated neuroendocrine carcinomas (NECs). Here, we provide an updated overview of the current knowledge regarding genomic profiles and representative agents for NENs and highlight the prospects for future investigations.

scholarly journals ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers

2017 ◽  
Vol 105 (3) ◽  
pp. 201-211 ◽  
Author(s):  
Kjell Oberg ◽  
Anne Couvelard ◽  
Gianfranco Delle Fave ◽  
David Gross ◽  
Ashley Grossman ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Biochemical Markers ◽  
Standards Of Care ◽  
Consensus Guidelines

scholarly journals ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes

2012 ◽  
Vol 95 (2) ◽  
pp. 98-119 ◽  
Author(s):  
Robert T. Jensen ◽  
Guillaume Cadiot ◽  
Maria L. Brandi ◽  
Wouter W. de Herder ◽  
Gregory Kaltsas ◽  
...  
Keyword(s):  
Endocrine Tumor ◽  
Pancreatic Endocrine Tumor ◽  
Neuroendocrine Neoplasms ◽  
Consensus Guidelines

scholarly journals Management of Brain and Leptomeningeal Metastases from Breast Cancer

2020 ◽  
Vol 21 (22) ◽  
pp. 8534
Author(s):  
Alessia Pellerino ◽  
Valeria Internò ◽  
Francesca Mo ◽  
Federica Franchino ◽  
Riccardo Soffietti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Systemic Therapy ◽  
Chemotherapeutic Agents ◽  
Leptomeningeal Metastases ◽  
Targeted Agents ◽  
Molecular Subgroups ◽  
Extracranial Disease ◽  
Selection Of Patients ◽  
Selection Of

The management of breast cancer (BC) has rapidly evolved in the last 20 years. The improvement of systemic therapy allows a remarkable control of extracranial disease. However, brain (BM) and leptomeningeal metastases (LM) are frequent complications of advanced BC and represent a challenging issue for clinicians. Some prognostic scales designed for metastatic BC have been employed to select fit patients for adequate therapy and enrollment in clinical trials. Different systemic drugs, such as targeted therapies with either monoclonal antibodies or small tyrosine kinase molecules, or modified chemotherapeutic agents are under investigation. Major aims are to improve the penetration of active drugs through the blood–brain barrier (BBB) or brain–tumor barrier (BTB), and establish the best sequence and timing of radiotherapy and systemic therapy to avoid neurocognitive impairment. Moreover, pharmacologic prevention is a new concept driven by the efficacy of targeted agents on macrometastases from specific molecular subgroups. This review aims to provide an overview of the clinical and molecular factors involved in the selection of patients for local and/or systemic therapy, as well as the results of clinical trials on advanced BC. Moreover, insight on promising therapeutic options and potential directions of future therapeutic targets against BBB and microenvironment are discussed.

scholarly journals ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum

2016 ◽  
Vol 103 (2) ◽  
pp. 125-138 ◽  
Author(s):  
B. Niederle ◽  
U.-F. Pape ◽  
F. Costa ◽  
D. Gross ◽  
F. Kelestimur ◽  
...  
Keyword(s):  
Neuroendocrine Neoplasms ◽  
Consensus Guidelines

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations

2009 ◽  
Vol 90 (2) ◽  
pp. 167-183 ◽  
Author(s):  
Anders Sundin ◽  
Marie-Pierre Vullierme ◽  
Gregory Kaltsas ◽  
Ursula Plöckinger
Keyword(s):  
Neuroendocrine Tumors ◽  
Standards Of Care ◽  
Consensus Guidelines ◽  
Radiological Examinations
Sign in / Sign up

Export Citation Format

Share Document